This paper is the twenty-ninth consecutive installment of the annual review of research concerning the endogenous opioid system, now spanning thirty years of research. It summarizes papers published during 2006 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurological disorders (Section 11); electrical-related activity and neurophysiology (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration and thermoregulation (Section 16); and immunological responses (Section 17).
2. Endogenous Opioids and Receptors
2a. Molecular-biochemical effects
This sub-section will review current developments in the molecular and biochemical characteristics of opioid peptides and receptors by subtypes: mu agonists and receptors (2a-i), delta agonists and receptors (2a-ii), kappa agonists and receptors (2a-iii), and OFQ/N and the ORL-1 receptor (2a-iv).
2a-i. Mu agonists and receptors
Endocytosis of the MOR-1D splice variant as well as DOR and the CB1 receptor is mediated by an agonist-independent and constitutive PLD2 activation (
604). Separation of MOR desensitization and internalization effects was demonstrated with endogenous receptors in primary neuronal LC cultures (
40). Exons 11 and 1 promoters of the MOR gene were characterized in transgenic mice (
1249). The splice variants of MOR, SV1 and SV2 do not exhibit binding to [3H] diprenorphine (
212). Five single nucleotide polymorphisms were identified for the MOR promoter, and no differences in construct activity were found in control and morphine-treated animals (
297). MOR-effector coupling and trafficking occurred in DRG neurons with DAMGO producing greater internalization in MOR/partial differential opioid receptors (
1180). MOR-DOR functional interactions occur through receptor-G (i1) alpha fusion (
1051). The poly C binding protein 1 is a regulator of the proximal promoter of the mouse MOR gene (
716). There is interplay between Sps and poly C binding protein 1 on MOR gene expression (
960). The neuron-restrictive silencer factor interacts with Sp3 to synergistically repress the MOR gene (
577). Mitochondrial damage decreases MOR, but not DOR function in neuronal SK-N-SH cells (
941). Diffusion of MOR at the surface of human neuroblastoma SH-SY5Y cells is restricted to permeable domains (
990). Differences in the intracisternal A-particle element in the 3′ noncoding region of the MOR gene in CXBK mice appear to cause this relatively insensitive phenotype (
446). Although 14-methoxymetopon displayed similar binding affinities for multiple splice variants of the MOR gene, its potency varied widely for the same splice variants (
713). MOR activation of ERK ½ is GRK3 and arrestin dependent in striatal neurons (
712). Introduction of a hydroxyl group in position 2 of the cyclohexyl residue of spiropiperidine decreased the binding affinity of mu receptors and OFQ/N (
177). Morphine displays PKC-dependent and DAMGO displays GRK2-dependent mechanisms of MOR desensitization in human embryonic kidney 293 cells (
529). Null and operational models of mu opioid binding in the mouse vase deferens revealed that DAMGO and DALDA were full agonists while morphine and endomorphin derivatives acted as partial agonists (
967). There is direct nose-to-brain transfer of morphine after nasal administration to rats (
1216). Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused liver preparation (
291). Greater in vitro inhibition of M6G relative to M3G formation from morphine occurred following treatment with (R)- and (S)-methadone and structurally related opioids (
804). M6G was identified in chromaffin cell secretory granules (
411). Mu opioid receptors are activated by Vitex agnus-castus methanol extracts (
1204). Binding of [(
35) S] GTPgammaS is stimulated by endomorphin-2 and morphiceptin analogs (
343). An aequorin luminescence-based calcium assay gives pharmacologically-relevant data for mu and delta opioid agonists without involving radioactivity or animal tissues (
344). The latter assay also indicated that D-1-Nal or D-2-Nal substitutions in position 4 of endomorphin-2 produced mu receptor antagonists, whereas substitution in position 3 produced partial agonists (
346). The tripeptides, Tyr-Pro-Ala-NH2 and Tyr-Pro-Ala-OH, which do not bind to mu receptors, are potent inhibitors of endomorphin degrading enzymes in the brain (
345). A partial agonistic effect of 9-hydroxycorynatheidine was observed on MOR in the guinea pig ileum (
747). Synthesis, radio labeling and receptor binding was accomplished for [3H] [(1S, 2R) ACPC2] endomorphin-2 (
569).
MOR, DOR and KOR binding properties were observed for 8-[N-(4′-phenyl)-phenethyl) carboxyamido] analogues of cyclazocine and ethylketocyclazocine (
1214). Pharmacokinetics of morphine was slower in flounder than in trout (
837). A direct and sensitive analysis of morphine, codeine and other bioactive drugs in human urine was performed by cation-selective exhaustive injection and sweeping micellar electrokinetic chromatography (
671). Alkyl chain length altered mu opioid activity of 3, 6-bis {H-Tyr/H-Dmt-NH (CH2) m, n]-2(1H) pyrazinone derivatives (
1031). Determination of human urinary opiates occurred with application of poly (methacrylic acid-ethylene gycol dimethacrylate) monolith micro extraction coupled with capillary zone electrophoresis (
1207). Urinary excretion of morphine and codeine occurred following the administration of single and multiple doses of opium preparations prescribed in Taiwan as “brown mixture” (
680). There are natural heroin impurities derived from tetrahydrobenzylisoquinoline alkaloids (
1128). [Sar2] endomorphin-2 was almost equipotent to the parent peptide in mu opioid receptor binding, and was highly resistant to enzymatic degradation (
512). Morphine-3-O-propionyl-6-O-sulfate had four times greater affinity than morphine at the MOR (
248). Mu opioid binding can be detected in a competitive displacement assay using a beta-imager (
916). Identification of potent phenyl imidazoles such as 4-aminocarbonyl-2, 6-dimethyl-Phe as opioid receptor agonists was completed (
133). A class of 4-substituted-8-(2-phenyl-cyclohexyl)-2-8-diaza-spiro[4,5]decan-1-one inhibitors was designed achieving antagonist selectivity against the mu opioid and ORL1 receptors (
15) that show improved metabolic stability (
16) and superior pharmacological and pharmacokinetic properties (
17). Chimeric peptides containing a mu opioid receptor ligand and an ORL-1 receptor ligand, Ac-RYYRIK-amide were synthesized (
560). Derivatives of 14-aminomorphinones with substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones produced potent mu agonists (
844).
A novel mu opioid antagonist was created by replacement of the N-terminal tyrosine residue in opioid peptides containing 3-(2, 6-dimethyl-4-carbamoylphenyl) propanoic acid (Dcp) results in a novel mu opioid antagonist (
701). Lysine at the C-terminus of the Dmt-Tic opioid pharmacophore produced new lead compounds in the formation of opioid peptidomimetics (
57). Multiple ligands from Dmt-Tic and morphinan pharmacophores produced agonists with MOR, KOR and DOR properties (
836). Whereas maximal stimulation of [35S]GTPgammaS binding decreased in canine thalamic and spinal cord homogenates for mu > ORL1 > kappa > delta opioid compounds, cortical homogenates showed an affinity order of kappa > ORL1 > delta > mu (
650). Morphine increased 5HT, Na (+), K (+)-ATPase activity differentially as a function of adulthood and adolescence (
432), and reduced human 5-HT3A receptors in an ondansetron assay (
1225). Bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta and kappa opioid receptors were developed and synthesized in an in vitro assay (
895). Potent and highly selective chiral tri-amine and tetra-amine MOR ligands were identified by lead optimization using mixture-based libraries (
831). Opioid and CCK receptors also have overlapping pharmacophores required for binding affinity and biological activity (
8). QSAR studies were performed upon 4-phenylpiperidine derivatives as mu opioid agonists by a neural network method (
1194). A HPLC assay for morphine was developed in small plasma samples (
293). Morphine concentrations in bone marrow paralleled plasma morphine concentration for up to 14 days after death in rabbits (
178). Unbound concentrations of oxycodone were three times higher in brain than in blood, indicating active influx at the blood-brain barrier (
118). An implantable buprenorphine delivery system was characterized using in vitro and in vivo techniques (
594). Capillary electrophoresis contributed to the identification of HMOR-3O-glucide and N-oxides in hydromorphone metabolism in humans (
58). STW 5 (Iberoglast) binds to intestinal 5-HT, muscarinic M3 and opioid receptors (
1038). A member of the heat shock protein 40 family, hlj1, binds to the carboxyl tail of the human MOR (
31).
Pre-POMC cDNA from the ostrich pituitary gland was sequenced revealing the positions for gamma-MSH, ACTH, AMSH, gamma-LPH, beta-MSH and BEND (
824). PC1/3 and PC/2 gene expression and post-translational endoproteolytic POMC processing is regulated by photoperiod in the seasonal Siberian hamster (
465). BEND analysis in the hypothalamus or PAG is not affected by diurnal variation (
348). BEND is present in the stallion testis, but appears to be derived from POMC gene expression in the pituitary (
1057). Three POMC subtype genes and subsequent peptides were identified in the pars distalis and intermedia of the barfin flounder pituitary (
1101). TAN-821 and TAN-1014 have been developed respectively as agonists and antagonists of the putative epsilon receptor (
368).
Histamine was released during constant rate infusion of morphine in dogs (
423). Cholinergic nicotinic stimulation of endogenous morphine release occurs from lobster nerve cord (
1327). Dextrorotatory morphinans inhibited alpha3beta4 nicotinic Ach receptor subunit cRNAs-induced inward currents in the presence of Ach in Xenopus oocytes (
639). Myristoylated G proteins (Galphai1 and GalphaoA) were maximally activated by DAMGO, Menk and Lenk, whereas endomorphin-1 and –2 as well as BEND produced strong, but not maximal responses. Morphine, methadone, fentanyl and buprenorphine produced statistically significant activation (
983). 3-aminopropionyl substituted fentanyl analogs were synthesized and displayed opioid activity (
906). New hybrid derivatives of fentanyl were found to be active at the MOR and I2-imidazoline binding sites (
261). Buprenorphine and norbuprenorphine display in vivo glucuronidation as determined by liquid chromatography-electrospray ionization-tandem mass spectrometry (
488). An immunalysis microplate ELISA was validated for the detection of buprenorphine and its metabolite norbuprenorphine in urine (
778). Opioid disposition occurs in human sweat after controlled oral codeine administration (
1003). CYP2D6-dependent formation of morphine does not exclusively explain the central effects of codeine; codeine-6-glucuronide is an additional active moiety (
696). Pharmacokinetic modeling of oxycodone in sheep displayed delayed equilibration between brain and blood levels that would be affected by changes in both cerebral blood flow and blood brain barrier permeability (
1164). The principal metabolic pathway of oxycodone in humans is CYP3A-mediated N-demethylation, but circulating oxidative and reductive metabolites provide a negligible contribution to central opioid effects (
627). The use of PTX-insensitive Galpha mutants revealed that the potency for mu agonists was highest for cells expressing Galpha (i3) and Galpha (o) and lowest with Galpha (i1) and Galpha (i2) (
228). NalBzOH displays agonist activity at MOR, DOR and KOR, but not ORL-1 receptors expressed either in a heterologous cell system or in a native environment (
862). FK33–824, a mu opioid agonist decreases enzymatic activity of PKC, adenylate cyclase and PKA in porcine granulosa cells (
546). The anti-opioid actions of NPVF, a NPFF agonist was observed in a decrease to opioids to voltage-gated (N-type Ca2+ currents and enhancement of muscarinic-induced intracellular Ca2+ release in SH-SY5Y cells as they do in neurons (
570).
Naltrexone increased PKCepsilon, ERK and integrin alpha 7 in SH-SY5Y neuroblastoma cells (
857). Long-acting naltrexone had a 1-month pharmacokinetic activity in plasma that was proportional to dose and number of treatments (
302). The dissociation of [3H] naloxone was four times faster under displacement than under infinite dilution conditions, demonstrating the retention effect of receptors confined in space (
1061). Naltrexone release from biodegradable microspheres produced constant rates of release culminating in 80% over 2 months (
691). Two novel tripartite codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion were synthesized as potential alcohol abuse and smoking cessation agents (
440). Transdermal delivery of 6-beta-naltrexol was enhanced by a codrug linked to hydroxybupropion (
588). MOR antagonists were synthesized and evaluated from novel octahydro-1H-pyrido [1, 2-a] pyrazine (
633) and from N-substituted trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperadine (
634). The permeation of nalmefene hydrochloride was better across the middle turbinate, posterior septum and superior turbinate mucosa (
301).
2a-ii. Delta agonists and receptors
Knock-in mice expressing fluorescent DOR uncovered G protein-coupled receptor dynamics in vivo (
996). Simultaneous activation of DOR and the sensory neuron-specific receptor-4 hetero-oligomer by the mixed bivalent agonist BAM-22 activates the latter, but inhibits the former (
132). Morphine and pain-related stimuli enhance cell surface availability of somatic DOR in rat dorsal root ganglia (
393). Delta and mu opioid receptors were cloned, heterologously expressed and pharmacologically characterized from the brain of a urodele amphibian, the rough-skinned newt, Taricha granulosa (
127). Adenosine A1 and A2 receptor agonists increase c-fos in striatal GABAergic Enk, but not GABAergic DYN striatal neurons as well as increasing striatal PreEnk (
553). The enrichment by 18-fold with FACS robustly increased beta-arrestin-1-GFP expression associated with strong human DOR desensitization (
10). A new duplicate DOR in zebra fish was characterized (
911). Enk and SP are found in reduced concentrations in primary culture striatal neurons relative to adult preparations (
330). The mGluRI antagonists, LY367385 and MPEP reduce NMDA-induced expression of the Pro-Enk gene in neocortex, yet enhance AMPA-induced expression of the neocortical Pro-Enk gene (
674). Pro-enk was identified in the hypothalamus and striatum using a method allowing selective isolation of neuropeptides of murine brains lacking carboxypeptidase E (
268). ProEnk A 119–159 is a stable ProEnk A precursor fragment identified in human circulation (
323). Only the C-terminus glucose conjugate of Lenk showed transport by glucose transporters and hPepT1 (
1237). Whereas only a few samples of adherent human fetal chromaffin cells expressed Menk early in vitro, almost all of the neurosphere-like colonies appearing later expressed Menk (
1321). Human Menk binds to anionic phosphatidylserine in high preference to zwitterionic phosphatidylchlorine in large unilamellar vesicles (
586). Lenk binds in a turn confirmation to DOR, but it is not a (
1–
4) beta-turn (
108). Nasal administration of Lenk is facilitated by a thiolated polycarbophil that slows Lenk degradation (
82), and reversible lipidization is preferable for the oral delivery of Lenk (
1185). 6-N, N-dimethylamino-2, 3-napthalimide was identified as a new environment-sensitive probe in delta- and mu-selective opioid peptides (
1149). The novel, orally active, DOR agonist, RWJ-394674 is biotransformed to the potent MOR agonist RWJ-413216 (
229). Highly potent and selective phenylmorphan-based inverse agonists of the DOR were developed (
1117). AUF-1 is expressed in the developing brain, binds to AT-rich double-stranded DNA, and regulates Enk gene expression (
287). Design and synthesis were completed of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK1/CCK2 receptor antagonists (
641). Three types of latex nanoparticles carrying NTI derivatives were identified as possessing high DOR affinity (
453). A new method using HPLC with electrochemical detection was developed allowing for the simultaneous measurement of Menk, Lenk, endomorphin-1 and endomorphin-2 (
677).
Selective alkylation of delta-2 opioid receptors occurred following NAC 5′Nti-isothiocyanate in the NAC and ventral caudate; beta-chlornaltrexamine was nonselective for MOR and DOR in the same site (
734). Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human DOR was described (
900). Pertussis-toxin abolished DPDPE-induced inhibition of forskolin-stimulated intracellular cAMP production that was rescued by Galpha (i2), but not Galpha (i3) or Galpha (o) mutants; the former, but not latter mutants co-precipitated with DOR. Long-term DPDPE treatment allowed pertussis toxin-induced elimination of naloxone-induced superactivation of adenylyl cyclase activity, an effect again rescued by Galpha (i2) mutants (
1311). DPDPE, acting through Gi-coupled DOR receptors mediate phosphorylation of CPI-17 and MLC20 through preferential activation of the PI3K/ILK pathway (
486). Down-regulation of the glutamate transporter EAAC1 occurred following expression and activation of the DOR and its agonist, DPDPE (
1240). Genetically-engineered human mesenchymal stem cells produce Menk at augmented higher levels in vitro (
1078). Lenk caused membrane currents across lipid membranes through adsorption, transportation and desorption, effects confirmed using fluorescence spectrometry and confocal laser scanning microscopy (
687). DADL induces a reversible hibernation-like state in HeLa cells (
1152). DADL molecules enter the cytoplasm and nucleus of LNCap cells that are devoid of opioid receptors, and binds to perichromatin fibrils where transcription and early splicing of pre-mRNAs and pre-rMRNAs occur, thereby resulting in decreased transcription and proliferation without apoptosis (
59). AVP enhances PAG synthesis and secretion of Enk and BEND, but not DYN (
1263).
2a-iii. Kappa agonists and receptors
KOR activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes (
141). Netrin-1 signaling regulates de novo protein synthesis of KOR by facilitating polysomal partition of its mRNA (
1133). Naloxone and NBNI, but not selective mu or delta antagonists increased, whereas DYN decreased the cell surface level of the human KOR by activation-induced down-regulation and pharmacological chaperone-mediated enhancement (
200). KOR affinity in a human embryonic kidney cell system indicated a rank order of cyclazocine, naltrexone, SKF10047, xorphanol, WIN44441, nalorphine, butorphanol, nalbuphine, lofentanil, dezocine, metazocine, morphine, hydromorphone and fentanyl (
399). A cDNA encoding KOR in zebra fish has been cloned and characterized (
27). GEC1 interacts with the kappa opioid receptor and enhances its expression (
188). Big DYN, a 32-amino acid Pro-DYN peptide consisting of DYN A and DYN B showed similar selectivity for human KOR as DYN A, was less selective than DYN A for human MOR, DOR and ORL1, but activated G proteins more potently than DYN A; DYN B was less potent and selective (
771). Big DYN and DYN A, but not DYN B causes leakage effects in large unilamellar phospholipid vesicles thereby causing perturbations in the lipid bilayer (
490). DYN A inserts its N-terminus into the bilayer of the bicelle, whereas DYN B resides on the surface of the bilayer (
673). Bikunin was identified as an endogenous inhibitor of DYN convertase in human cerebrospinal fluid (
1077). Although selective opioid agonists developed for mammalian opioid receptors did not fully recognize opioid binding sites in zebra fish brain, DYN A showed good affinities in the nanomolar range (
409). Pro-DYN cDNA’s were cloned in eels and tilapia (
24).
NalBzOH binding is abolished in triple MOR/KOR/DOR mice, and in vivo changes reflect that of a nonselective opiate drug (
235). N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists (
171). New C (
4)-modified salvinorin A analogues were synthesized as KOR agonists (
636). Salvinorin A analogues were also synthesized following effects of configuration at C (
2) and substitution at C (
18) (
73) along with those isolated from Salvia divinorum (
1120). Salvinorin A, a selective KOR agonist was used in a combined ligand-based and target-based drug design approach for G-protein coupled receptors (
1041). A unique binding epitope was found for salvinorin A, a non-nitrogenous KOR agonist (
548). Bioisosteric modification of the C-2 thioacetate isoester of salvinorin A produced a potent and selective KOR agonist (
1070). The substitution of a tert-butyl with a cyclobutyl moiety in buprenorphine created a highly selective KOR agonist with low addictive potential and dependence liability (
877). 3D-QSAR studies were performed upon orvinol analogs as kappa-opioid agonists (
656). The extraction fraction for NAC DA in the mouse is increased following NBNI treatment (
186). The application of Schild-analysis to the antagonism of U50488H by NBNI provides pharmacological evidence for KOR in Planaria (
934).
2a-iv. OFQ/N and ORL-1 receptor
OFQ/N binding to ORL-1 receptors triggers internalization of these components into vesicular compartments that is dependent on PKC and occurs selectively for N-type calcium channels (
25). OFQ/N, but not partial agonists induce concentration-dependent endocytosis and recycling of the human ORL1 receptor, enhancing up regulation of adenylyl cyclase activity (
1059). OFQ/N differentially activates ERK, p38 and JNK MAPK to contribute to potentiations of prostaglandin vasoconstriction after fluid percussion brain injury (
38). The induction of Pro-OFQ/N mRNA by cAMP appears to be mediated by a cAMP-response element, histone acetylation and through CREB (
1301). The ORL-1 receptor utilizes both G (oA) and G (oB) for signal transduction (
1136). OFQ/N and its agonist, Ro64-6198 display great regional similarities in binding assays using [(
35) S]-GTPgammaS binding (
390). OFQ/N and DYN A analogues with Dmp substituted for N-terminal aromatic residues show ORL-1 and opioid receptor preferences (
989). A novel D-proline amide class of spiropiperidines was developed as an effective ORL-1 antagonist (
410). OFQ/N (
1–
13) NH2 analogues modified in the 9 and/or 13 positions were synthesized and showed biological activity (
828). An enzymatically-resistant OFQ/N peptide containing a carbamic acid residue was synthesized (
665). Indole derivatives were designed, synthesized and biologically evaluated as novel OFQ/N receptor antagonists (
1079). Potential ORL-1 ligands were synthesized from spiro-[piperidine-4,2′(1′H)-quinazolin]-4′ (3′H)-ones and spiro-[piperidine-4,5′ (6′H)-[1,2,4]triazolo[1,5-c]quinazolines] (
809). Trap-101, an achiral analogue of J-113397 was identified as a potent ORL-1 antagonist (
1132). Both 3-(4-Piperidinyl) indoles and 3-(4-piperidinyl) pyrrolo-[2, 3-b] pyridines are ligands for the ORL-1 receptor (
96). A series of hexapeptides with a general formula of Ac-RYY-R/K-W/I-R/K-NH (
2) were identified as novel partial agonists for the ORL-1 receptor (
428).
BDNF induced expression of Pro-OFQ/N mRNA’s that in turn induced expression of immediate early genes in hippocampal cultures. OFQ/N, but not nocistatin increased both neurite length and number in hippocampal cultures (
954). Mature OFQ/N and nocistatin were identified in human brain and CSF (
534).
3. Pain and Analgesia